Recent developments in the fight against cancer have brought us to the exciting forefront of early detection through a simple blood test.
This test, called the Multicancer Early Detection (MCED) test, is currently under the microscope, explored for its potential in sniffing out cancer in its early stages in people who show no signs of the disease.
Testing the Waters: A Preliminary Glance at MCED Testing
In a study headed by Deb Schrag, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, researchers were eager to check how practical and reliable MCED testing could be in identifying cancer in its initial stages.
Over a year, from December 2019 to December 2020, they managed to bring together a group of 6,662 adults who were all 50 years or older.
None of these individuals showed symptoms or signs of cancer, making them an interesting group to observe.
Out of these, 6,621 participants had results that could be thoroughly analyzed. An interesting find was that 1.4% of these participants showcased a signal for cancer in their blood test results.
When digging deeper, 38% from this subgroup were indeed diagnosed with cancer, proving the test was on to something.
However, it wasn’t a full-proof method as 62% who showed a signal, upon further investigation, were not diagnosed with cancer.
The Snags Along the Way: True Positives vs. False Positives
In any scientific experiment, especially those dealing with something as intricate and multifaceted as cancer detection, it’s vital to ensure the results are reliable.
In this case, the MCED testing demonstrated a significant number of false positives – cases where the test indicated a cancer signal but was not validated upon further inspection.
This raised questions and considerations regarding the emotional and medical implications for the individuals tested, as it takes, on average, 162 days to resolve a false positive, in comparison to 57 days for true positives.
Most participants, whether true positive or false positive, underwent a battery of additional laboratory tests and imaging procedures to confirm or refute the initial blood test findings.
Those with false-positive results underwent notably fewer subsequent procedures compared to those who were ultimately diagnosed with cancer.
A Glimpse into the Future: What’s Next for MCED Testing?
While this study cracked open the door to the possibility of utilizing MCED testing as a feasible method for early cancer detection, it also highlighted a few stumbling blocks along the way.
The researchers note that while the concept has been proven possible, there’s a need for much larger and extensive studies to confidently say that MCED testing could be a regular and reliable tool in detecting cancer and, more importantly, in reducing cancer-related deaths.
This initial study is a stride towards a future where a simple blood test could perhaps alert individuals to the silent onset of cancer, paving the way for earlier intervention and treatment.
However, the journey is far from over, and the medical and scientific communities will be keenly observing subsequent larger studies to paint a clearer picture of MCED testing’s true potential in the battle against cancer.
This journey symbolizes the tireless pursuit of the medical community in finding new allies and tools in the ongoing battle against cancer, ensuring earlier detection, and subsequently, improving the chances and quality of life for countless individuals across the globe.
If you care about cancer, please read studies about common drugs for inflammation may help kill cancer, and statin drugs can starve cancer cells to death.
For more information about cancer prevention, please see recent studies about nutrient in fish that can be a poison for cancer, and results showing this daily vitamin is critical to cancer prevention.
The research findings can be found in The Lancet.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
